

AMICUS THERAPEUTICS INC
 Form 3
 December 03, 2013

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL
 OMB Number: 3235-0104
 Expires: January 31, 2015
 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *		2. Date of Event Requiring Statement	3. Issuer Name and Ticker or Trading Symbol	
Â Yu Julie		(Month/Day/Year)	AMICUS THERAPEUTICS INC [FOLD]	
(Last)	(First)	(Middle)	12/02/2013	
C/O AMICUS THERAPEUTICS			4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)			(Check all applicable)	
CRANBURY,Â NJÂ 08512			<input type="checkbox"/> Director <input type="checkbox"/> 10% Owner	6. Individual or Joint/Group Filing(Check Applicable Line)
(City)	(State)	(Zip)	<input checked="" type="checkbox"/> Officer <input type="checkbox"/> Other	<input checked="" type="checkbox"/> Form filed by One Reporting Person
			(give title below) (specify below)	<input type="checkbox"/> Form filed by More than One Reporting Person
			Vice President Clinical Ops	

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable Expiration Date	Title Amount or Number of Shares			

Edgar Filing: AMICUS THERAPEUTICS INC - Form 3

Stock options (right to buy)	Â (1)	02/13/2022	Common stock	25,000	\$ 6.45	D	Â
Stock options (right to buy)	Â (2)	06/04/2022	Common stock	12,500	\$ 4.38	D	Â
Stock options (right to buy)	Â (3)	01/28/2023	Common stock	13,750	\$ 3.53	D	Â
Stock options (right to buy)	Â (4)	06/18/2023	Common stock	13,750	\$ 2.52	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Yu Julie C/O AMICUS THERAPEUTICS CRANBURY, NJ 08512	Â	Â	Â Vice President Clinical Ops	Â

Signatures

/s/ Julie Yu 12/03/2013

**Signature of
Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

These options vest and become exercisable in a series of installments. The first installment, which consists of 25% of the total aggregate number of options granted, vests on February 13, 2013. The remaining options vest and become exercisable in a series of thirty-five successive equal monthly installments, beginning on March 1, 2013, with the final installment vesting on February 1, 2016.

These options vest and become exercisable in a series of installments. The first installment, which consists of 25% of the total aggregate number of options granted, vests on June 4, 2013. The remaining options vest and become exercisable in a series of thirty-five successive equal monthly installments, beginning on July 1, 2013, with the final installment vesting on June 1, 2016.

These options vest and become exercisable in a series of installments. The first installment, which consists of 25% of the total aggregate number of options granted, vests on January 28, 2014. The remaining options vest and become exercisable in a series of thirty-five successive equal monthly installments, beginning on February 1, 2014, with the final installment vesting on January 1, 2017.

These options vest and become exercisable in a series of installments. The first installment, which consists of 25% of the total aggregate number of options granted, vests on June 18, 2014. The remaining options vest and become exercisable in a series of thirty-five successive equal monthly installments, beginning on July 1, 2014, with the final installment vesting on June 1, 2017.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.